IDEAYA Biosciences Unveils New Inducement Grants Under Nasdaq Regulations

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a pioneering name in the field of precision medicine oncology, has recently made headlines with their announcement on September 25, 2025. The company revealed that its Board of Directors' Compensation Committee approved the grant of non-qualified stock options to a newly hired employee, which will allow them to purchase a total of 31,400 shares of IDEAYA’s common stock. This decision is part of a larger strategy to attract talent under the auspices of Nasdaq Listing Rule 5635(c)(4).

The grants were made under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan, a program specifically designed to incentivize individuals joining the company by offering equity in the firm. Uniquely tailored for those who have either never been employed by IDEAYA before or who are returning after a bona fide period of non-employment, this plan aims to create an enticing workplace environment that fosters growth and commitment.

These stock options have an exercise price set at $25.69 per share, mirroring the closing price of IDEAYA's stock on The Nasdaq Global Select Market on the day of grant. With a generous 10-year term, these options will vest over a four-year period. The vesting schedule allows for an initial 25% of the options to vest on the first anniversary of the commencement date, with the remaining 75% vesting in monthly increments across the following three years. Importantly, continued service at IDEAYA is required for each vesting date.

About IDEAYA Biosciences

IDEAYA Biosciences specializes in the discovery, development, and commercialization of transformative therapies targeted at cancer. Their innovative approach blends expertise in small-molecule drug research, structural biology, and bioinformatics with robust internal capabilities designed to identify and validate translational biomarkers essential in developing potentially first-in-class targeted therapies. This synergy leverages the genetic drivers of disease to create highly effective, personalized treatments.

Their expansive pipeline focuses on synthetic lethality and antibody-drug conjugates (ADCs), targeting specific solid tumor indications. IDEAYA’s ultimate mission is to revolutionize precision oncology with therapies that are not only more selective and effective but also deeply tailored to the individual patient’s needs. This goal underscores their commitment to improving clinical outcomes for cancer patients, ultimately altering the disease's trajectory.

Moreover, IDEAYA is continuously engaging with the investment community and other stakeholders through transparent communication, providing insights into their strategic initiatives and advancements.

For further information, stakeholders and media personnel may contact IDEAYA Biosciences’ Chief Financial Officer, Dr. Joshua Bleharski, directly via email at the provided address, fostering a proactive dialogue as the company embarks on its next chapter of innovation in oncology.

As IDEAYA moves forward, maintaining a focus on talent acquisition and employee engagement through such grant initiatives reinforces the critical link between sustainable growth in the biotech sector and the importance of human capital in achieving strategic goals.